Medicus Pharma Ltd (NASDAQ:MDCX) Given Average Rating of “Hold” by Analysts

Medicus Pharma Ltd (NASDAQ:MDCX) has received an average rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $9.00.

MDCX has been the subject of several recent analyst reports. Roth Capital initiated coverage on shares of Medicus Pharma in a research note on Tuesday, April 21st. They set a “buy” rating for the company. Alliance Global Partners assumed coverage on Medicus Pharma in a research report on Tuesday. They set a “buy” rating for the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th.

Medicus Pharma Stock Up 4.8%

Medicus Pharma stock opened at $0.28 on Tuesday. Medicus Pharma has a twelve month low of $0.25 and a twelve month high of $3.05. The firm has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.61. The company has a market capitalization of $15.59 million, a PE ratio of -0.10 and a beta of -0.05.

Medicus Pharma (NASDAQ:MDCX) last issued its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). As a group, equities analysts expect that Medicus Pharma will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Medicus Pharma

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new stake in Medicus Pharma in the fourth quarter worth approximately $2,771,000. Private Advisor Group LLC grew its holdings in Medicus Pharma by 36.8% during the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after purchasing an additional 64,560 shares during the period. Jane Street Group LLC bought a new position in shares of Medicus Pharma during the 4th quarter valued at approximately $92,000. HRT Financial LP bought a new position in shares of Medicus Pharma in the fourth quarter worth approximately $42,000. Finally, Wilmington Savings Fund Society FSB increased its stake in Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after buying an additional 25,622 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.